Rubén Díez is Co-Founder and CFO at Telum Therapeutics, a Spanish biotechnology company pioneering engineered phage lytic proteins to combat multidrug-resistant bacterial infections.

Rubén built a strong financial career at leading institutions including Banco Santander and CESCE, gaining deep expertise in corporate finance and business strategy before co-founding Telum.

Rubén brings the financial discipline and business acumen that complements Telum's deep scientific expertise, helping bridge the gap between cutting-edge biotech innovation and investor-ready strategy.

As CFO, Rubén has helped secure over 22 million euros in funding, including a 4.1 million euro seed round in 2020 and an 18 million euro Series A in 2026 led by the AMR Action Fund.

Telum's proprietary APEX platform, powered by synthetic biology and generative AI, is advancing a lead program into Phase 1 clinical trials targeting deadly hospital-acquired and ventilator-associated bacterial pneumonia.